NCT00396331 · REGISTRY CONDITION SEARCH

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2014-03-13

This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients who would benefit from an autologous stem cell transplant but have failed previous collections or collection attempts with a mobilization regimen of G-CSF alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests. The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of AMD3100 (plerixafor) on the evening prior to each day of apheresis. Efficacy outcomes include quantification of CD34+ cells in the apheresis product and assessment of successful polymorphonuclear leukocyte (PMN) and platelet (PLT) engraftment after transplantation. PK outcomes include analysis of repeated doses of plerixafor.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period

→

outcome · POSTED

Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

→

outcome · POSTED

Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment

→

outcome · POSTED

Median Number of Days to Platelet (PLT) Engraftment

→

outcome · POSTED

Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation

→

outcome · POSTED

Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF

→

outcome · POSTED

Number of Participants With Non-Hodgkin's Lymphoma (NHL) Who Had Evidence of Tumor Cell Mobilization After G-CSF or Plerixafor Administration

→

outcome · POSTED

Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF

→

outcome · POSTED

Number of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF

→

outcome · POSTED

Maximum Observed Plasma Concentration (Cmax) on Day 4

→

outcome · POSTED

Maximum Observed Plasma Concentration (Cmax) on Day 7

→

outcome · POSTED

Time to Maximum Plasma Concentration (Tmax) on Day 4

→

outcome · POSTED

Time to Maximum Plasma Concentration (Tmax) on Day 7

→

outcome · POSTED

Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4

→

outcome · POSTED

Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Eligible to undergo autologous transplantation * Has failed previous collections or collection attempts with a mobilization regimen of granulocyte colony-stimulating factor (G-CSF), chemotherapy and G-CSF or any other conventional therapy including cytokines, chemotherapy and cytokines or bone marrow harvest. * Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1 * ≥3 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study) NOTE: Although thalidomide, dexamethasone, and Velcade™ are not considered prior chemotherapy for the purpose of this study, none are to be administered within 7 days prior to the first dose of G-CSF (see Exclusion Criteria). * The patient has recovered from all acute toxic effects of prior chemotherapy * White blood cell count (WBC) \>2.5\*10\^9/L * Absolute neutrophil count \>1.5\*10\^9/L * Platelet count \>85\*10\^9/L * Serum creatinine ≤1.5 mg/dl * Creatinine clearance \>60 ml/min * Aspartate aminotransferase (AST), alanine transaminase (ALT) and total bilirubin \<2x upper limit of normal (ULN) * Left ventricle ejection fraction \>45% (by normal echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan) * Forced expiratory volume in one minute (FEV1) \>60% of predicted or diffusion lung capacity for carbon monoxide (DLCO) ≥45% of predicted * No active infection of hepatitis B or C * Negative for HIV * Signed informed consent * Women of child-bearing potential agree to use an approved form of contraception Exclusion Criteria: * Once 70 patients have enrolled, patients with diagnoses other than lymphoma are not eligible (eg, acute myeloid leukemia, chronic lymphocytic leukemia, or multiple myeloma). * A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications * A residual acute medical condition resulting from prior chemotherapy * Received Neupogen™, thalidomide, dexamethasone, and/or Velcade™ within 7 days prior to the first dose of G-CSF * Brain metastases or carcinomatous meningitis * Acute infection * Fever (temperature \>38°C/100.4°F) * Hypercalcaemia (\>1 mg/dL above the ULN) * Positive pregnancy test in female patients * Lactating females * Patients of child-bearing potential unwilling to implement adequate birth control * Patients whose actual body weight exceeds 175% of their ideal body weight * Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the Mobilization phase
healthy Volunteers: false
maximum Age: 78 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

intervention Names
Drug: G-CSF plus plerixafor
label
G-CSF plus Plerixafor
type
EXPERIMENTAL

interventions

arm Group Labels
G-CSF plus Plerixafor
description
Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
name
G-CSF plus plerixafor
other Names
AMD3100
Mozobil
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 100
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').
measure
Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period
time Frame
Day 1 to approximately day 38
description
Proportion of participants who reached the target of at least 2\*10\^6 CD34+ cells/kg collected during up to 7 aphereses.
measure
Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
time Frame
Day 5 to Day 11 (up to 7 apheresis)
description
Proportion of participants who reached the target of at least 5\*10\^6 CD34+ cells/kg collected during up to 7 apheresis.
measure
Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
time Frame
Day 5 to Day 11 (up to 7 aphereses)

secondary Outcomes

description
The number of days from transplantation to successful engraftment as measured by PMN \>=0.5\*10\^9 /L for 3 days or \>=1.0\*10\^9 /L for 1 day.
measure
Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment
time Frame
approximately 2 months (1 month post transplant)
description
The number of days from transplantation to successful engraftment as measured by platelet value of \>=20\*10\^9/L for 7 days without transfusion.
measure
Median Number of Days to Platelet (PLT) Engraftment
time Frame
Approximately 2 months (1 month post transplant)
description
The number of participants maintaining a durable graft 12 months after transplantation. A durable graft was defined as maintenance of normal blood counts: PLT \>50\*10\^9/L without transfusion for at least 2 weeks prior to the visit; hemoglobin level \>= 10 g/dL with no erythropoietin or transfusions for at least 1 month prior to the visit; and absolute neutrophil count (ANC) \> 1,000 (1\*10\^9/L) with no G-CSF for at least 1 week prior to the visit.
measure
Number of Participants With Durable Engraftment 12 Months After Autologous Transplantation
time Frame
Approximately 13 months (12 months post transplant )
description
The number of participants with Bcl2 translocation in post-treatment samples.
measure
Number of Participants With Non-Hodgkin's Lymphoma (NHL) Who Had Evidence of Tumor Cell Mobilization After G-CSF or Plerixafor Administration
time Frame
Up to Day 7
description
Number of participants who had at least 2\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.
measure
Number of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF
time Frame
Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)
description
Number of participants who had at least 5\*10\^6 CD34+ cells/kg collected by apheresis during both the first and the second courses of treatment together.
measure
Number of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Collected During Both Courses of Treatment With Plerixafor and G-CSF
time Frame
Day 5 up to Month 6 (up to 7 aphereses in each course of treatment)
description
Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.
measure
Maximum Observed Plasma Concentration (Cmax) on Day 4
time Frame
Day 4 (following first plerixafor administration)
description
Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.
measure
Maximum Observed Plasma Concentration (Cmax) on Day 7
time Frame
Day 7 (following fourth plerixafor administration)
description
Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data
measure
Time to Maximum Plasma Concentration (Tmax) on Day 4
time Frame
Day 4 (following first plerixafor administration)
description
Time to maximum plasma concentration (Tmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data
measure
Time to Maximum Plasma Concentration (Tmax) on Day 7
time Frame
Day 7 (following fourth plerixafor administration)
description
Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.
measure
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 4
time Frame
Days 4 -5 (following first plerixafor administration)
description
Area under the steady-state plasma concentration time curve from time zero to the last quantifiable sample after each plerixafor daily dose of 240 µg/kg, determined using the linear trapezoidal rule.
measure
Area Under the Steady-state Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Sample (AUC0-last) on Day 7
time Frame
Days 7-8 (following fourth plerixafor administration)

Full study description

brief Summary: This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients who would benefit from an autologous stem cell transplant but have failed previous collections or collection attempts with a mobilization regimen of G-CSF alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests. The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of AMD3100 (plerixafor) on the evening prior to each day of apheresis. Efficacy outcomes include quantification of CD34+ cells in the apheresis product and assessment of successful polymorphonuclear leukocyte (PMN) and platelet (PLT) engraftment after transplantation. PK outcomes include analysis of repeated doses of plerixafor.
detailed Description: This is a Phase 2, multicenter, prospective, open-label study. Once 70 patients have enrolled, subsequent patients enrolled should have a diagnosis of lymphoma. Patients who would benefit from an autologous stem cell transplant, who have failed previous collections or collection attempts with a mobilization regimen of granulocyte colony-stimulating factor (G-CSF) alone, chemotherapy and G-CSF, or any other conventional therapy including cytokines, chemotherapy and cytokines and bone marrow harvests, and who meet the inclusion/exclusion criteria are eligible to receive plerixafor as outlined in this protocol. The only change to standard of care of a mobilization regimen that includes G-CSF is the addition of a dose of plerixafor on the evening prior to each day of apheresis. Patients will undergo mobilization with G-CSF (10 µg/kg) for 4 days. On Day 4, plerixafor (240 µg/kg) will be administered in the evening prior to the first apheresis and each subsequent evening prior to apheresis thereafter, such that there is a 10 to 11 hour interval between dosing and the initiation of apheresis. Patients will continue to receive G-CSF on each day of apheresis. Patients will undergo a minimum of 2 and a maximum of 7 aphereses or until ≥2\*10\^6 CD34+ cells/kg are collected, whichever occurs first. In addition, the mobilization of NHL tumor cells and the pharmacokinetics of repeat doses of plerixafor will be examined. After the last apheresis has been completed, or after the patient has collected ≥2\*10\^6 CD34+ cells/kg, he/she will be treated with high-dose chemotherapy in preparation for transplantation. Patients will be transplanted with cells obtained from the G-CSF with plerixafor mobilization regimen. In the event that the minimum number of ≥2\*10\^6 cells for transplantation are not obtained from the first mobilization with plerixafor, cells may be retained and pooled for transplantation with those from a second mobilization with plerixafor (or from prior mobilization with other agents), at the investigator's discretion. If a second mobilization with plerixafor is attempted, a minimum rest interval of one week should be allowed between the last apheresis of the first regimen and the first dose of G-CSF of the second. The number of CD34+ cells mobilized in the peripheral blood (PB), collected in the apheresis product, and the number of apheresis sessions performed will be measured. Success of the transplantation will be evaluated by the time to engraftment of polymorphonuclear leukocytes (PMN) and platelets (PLT). Participants will be assessed for durability of their transplant for 12 months after transplantation. This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-9cb69a5166427df67385
requested nct id
NCT00396331
primary nct id
NCT00396331
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
8aef2878bf8ec06e4ec64a9039a8d6de150c39343fb876a327155ae059a89ac3
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-9cb69a5166427df67385
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00396331
occurrences
context exact
NCT00396331
end
11
exact text
NCT00396331
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/380/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
760c30c4da556aa331d399503a755108b67432cb39cccb64532ec5b14efd6228
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice